Document is current
Any future updates will be listed below
-
Authors
Even, Caroline
Harrington, Kevin J https://orcid.org/0000-0002-6014-348X
Massarelli, Erminia
Laban, Simon https://orcid.org/0000-0001-6732-7137
Fayette, Jérôme https://orcid.org/0000-0002-8126-7019
Oliva, Marc
Klein Hesselink, Marielle
Visscher, Sonja
Fury, Matthew G
Wiekmeijer, Anna-Sophia
Licitra, Lisa https://orcid.org/0000-0003-0623-4118
Melichar, Bohuslav
Devriese, Lot A
Braña, Irene
Jankowska, Petra
Posner, Marshall https://orcid.org/0000-0003-1912-3281
Glisson, Bonnie
Kong, Anthony
Hooftman, Leon
Melief, Cornelis J M MD, https://orcid.org/0000-0001-5709-3584
Ferrarotto, Renata
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03669718 at ClinicalTrials.govDocuments that mention this clinical trial
ISA101 and nivolumab for HPV-16<sup>+</sup> cancer: updated clinical efficacy and immune correlates of response
https://doi.org/10.1136/jitc-2021-004232
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).
https://doi.org/10.1200/jco.2024.42.16_suppl.6003
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
https://doi.org/10.1136/jitc-2025-012555
-
Funding
Funding for this research was provided by:
ISA Pharmaceuticals (No grant/ award number)
Regeneron Pharmaceuticals (No Grant/ Award number)
- License Information
